In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foamix Pharmaceuticals Ltd.

www.foamix.com

Latest From Foamix Pharmaceuticals Ltd.

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies

Keeping Track: US FDA Receives Submissions Galore As Year Ends

A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Drug Review Regulation

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.

 

Research & Development Dermatology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Foamix Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Foamix Pharmaceuticals Ltd.
  • Senior Management
  • David Domzalski, CEO
    Ilan Hadar, CFO
    Matt Wiley, Chief Commercial Officer
    Russell Elliott, PhD, SVP, Pharmaceutical Dev.
    Iain Stuart, PhD, CSO
    Deepa Desai, VP, Reg. Affairs
  • Contact Info
  • Foamix Pharmaceuticals Ltd.
    Phone: (972) 8 9316233
    Weizmann Science Park
    2 Holzman St.
    Rehovot, 7670402
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register